Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
Abstract The aim of oral tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is to get ideal hematological, cytogenetic, molecular responses at the critical time-points. The depth of the response obtained with TKI and time to achieve this response are important for the predi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2014-08-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://mjhid.org/index.php/mjhid/article/view/1688 |